However, a 2007 study by Yuen et al. Determined antiviral treatment treatment with LAM is associated with a 76 percent drug – resistance rate after eight years. In recent years, studies have to be superior to entecavir in the reduction of HBV-DNA , as shown with only a 1.2 percent drug resistance after five years Lam.. The World Health Organization estimates that more than 2 billion people infected with HBV, about 360 million of these cases are chronic infection that could lead to liver cirrhosis and hepatocellular carcinoma .
Sources: Wiley – Blackwell, AlphaGalileo Foundation.. In the latest study, James Fung, and the team of Professor Man – Fung Yuen, led by the University of Hong Kong, it was examined whether first HBV DNA suppression could be due to the stronger antiviral agent, entecavir, by switching on LAM, a less potent and less costly antiviral be maintained. The potential for a drug resistance and viral rebound with sequential therapy of the two anti-viral therapies has also been examined.###The research was conducted by atherosclerosis, Thrombosis, and Vascular Biology online scientists from the Bronx NY Veterans Affairs Medical Center and the University of Michigan in Ann Arbor well as contributed the published study. Henry J. Kaiser Family Foundation 2005 Advisory Board Company and Kaiser Family Foundation, All Rights Reserved.
Results showed predictor of mortality help heart surgery patients of researchers.
The authors suggested several possible explanations for the paradoxical monitoring, including potential upregulation of the RANTES receptor, the CCR5 receptor , which is renowned for its proatherosclerotic qualities. Alternately may lower RANTES shall reflect only more depositing of RANTES to atherosclerosis arteries with fewer blood levels of to measure subroutine ELISA assays.